Alnylam Pharmaceuticals, Inc. vs ASML Holding NV — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.66 (market cap $29.60B), while ASML Holding NV trades at $1,825.37 (market cap $689.17B). The key difference: ASML Holding NV is far larger — about 23.3× Alnylam Pharmaceuticals, Inc.'s market cap, and ASML Holding NV pays a 0.5% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | ASML | |
|---|---|---|
Market Cap | $29.60B | $689.17B |
Sector | Health | Technology |
52-Week High | $491.22 | $1.99K |
52-Week Low | $205.48 | $725.85 |
Enterprise Value | $27.56B | $682.70B |
Dividend Yield | — | 0.5% |
Trailing returns across standard periods
Latest headlines on both assets
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →Founded in 1984 and based in the Netherlands, ASML is the leader in photolithography systems used in the manufacturing of semiconductors. Photolithography is the process in which a light source is used to expose circuit patterns from a photomask onto a semiconductor wafer. The latest technological advances in this segment allow chipmakers to continually increase the number of transistors on the same area of silicon, with lithography historically representing a meaningful portion of the cost of making cutting-edge chips. Chipmakers require next-generation EUV lithography tools from ASML to continue past the 5-nanometer process node. ASML's products are used at every major semiconductor manufacturer, including Intel, Samsung, and TSMC.
Read more on ASML →